Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for Metastatic Head and Neck Squamous Cell Carcinoma
Sites in Lebanon +184 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06589804·Phase 3·Recruiting·Listed Sep 2024